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ABSTRACT
Considerable interest has been focused on inducing
RNA interference (RNAi) in neurons to study gene
function and identify new targets for disease inter-
vention. Although small interfering RNAs (siRNAs)
have been used to silence genes in neurons,
in vivo delivery of RNAi remains a major challenge
limiting its applications. We have developed a highly
efficient method for in vivo gene silencing in dorsal
root ganglia (DRG) using replication-defective
herpes simplex viral (HSV-1) vectors. HSV-mediated
delivery of short-hairpin RNA (shRNA) targeting
reporter genes resulted in highly effective and spe-
cific silencing in neuronal and non-neuronal cells in
culture and in the DRG of mice in vivo including in a
transgenic mouse model. We further establish proof
of concept by demonstrating in vivo silencing of the
endogenous trpv1 gene. These data are the first to
show silencing in DRG neurons in vivo by vector-
mediated delivery of shRNA. Our results support
the utility of HSV vectors for gene silencing in
peripheral neurons and the potential application of
this technology to the study of nociceptive pro-
cesses and in pain gene target validation studies.
INTRODUCTION
RNA interference (RNAi) is an evolutionary conserved,
post-transcriptional gene silencing mechanism mediated
by two classes of small double-stranded RNA molecules:
small interfering RNAs (siRNAs) and microRNAs
(miRNAs). MiRNAs are endogenous, regulatory noncod-
ing RNA molecules involved in many developmental and
cellular functions (1–3) and have been recently implicated
in the pathogenesis of human disease, including neurode-
generative disorders (4). Unlike siRNAs that originate in
the cytoplasm, miRNAs are transcribed by RNA pol II as
part of a long primary miRNA transcript (pri-miRNA).
The pri-miRNA is processed in the nucleus by the enzyme
Drosha into a hairpin intermediate, termed precursor
miRNA (pre-miRNA), which is subsequently exported
to the cytoplasm (5,6). Both siRNAs and miRNAs are
generated by Dicer, and increasing evidence suggests
that they can act in the same manner to mediate similar
eﬀects (7–9).
The recent discovery that RNAi operates in mammalian
neurons (10) has generated great excitement, not only with
respect to potential applications in functional genomic
studies and target validation, but also in harnessing
RNAi as a therapeutic strategy to silence disease-causing
genes. Although delivery of synthetic siRNAs to the ner-
vous system has achieved silencing of molecular targets
in various models of neurological disease including pain
(11–13,14), it requires frequent administration and high
doses. As a more eﬃcient alternative, targeted delivery
of RNAi to neurons can be achieved using viral vectors.
Lentiviruses, adenoassociated viruses and more recently,
herpes simplex virus have been engineered to deliver short-
hairpin RNA (shRNA) to parts of the nervous system
(15–20,21). There are no reports, however, of vector-
mediated delivery of shRNA to dorsal root ganglion
(DRG) neurons in vivo, the main target site for studying
nociceptive processes or for the development of new
analgesics.
Herpes simplex virus (HSV-1) is a naturally neuro-
trophic double-stranded DNA virus able to establish
life-long latency in neurons. Unlike other viruses that
infect neurons, HSV has evolved to be eﬃciently trans-
ported from the nerve terminals innervating the infection
site to cell bodies in vivo and has therefore proven parti-
cularly eﬃcient at targeting neurons of the DRG following
injection into the sciatic nerve. We have previously shown
that replication-defective HSV-1 vectors can transduce
neurons, and a broad range of non-neuronal cells in cul-
ture, with high eﬃciency, without viral gene expression or
toxicity. Deletion of the essential immediate-early (IE)
gene ICP4 results in replication-defective viruses. To mini-
mize cytotoxicity, the vectors also contain an inactivating
mutation in the gene encoding VP16, which abolishes
transactivation of the remaining IE genes (22,23). These
vectors are easily produced to high titres using a
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the equine herpes virus homologue of VP16 (24). In vivo,
the temporal cascade of viral gene expression is incapable
of proceeding past the IE phase resulting in vectors that
can establish a persistent state very similar to latency but
are unable to reactivate and therefore persist for long peri-
ods of time. In addition, by inserting a strong heterolog-
ous promoter 1.4kb downstream of the LAP1 TATA box,
a region referred to as LAT P2, we have developed pro-
moter systems that allow prolonged expression of exogen-
ous genes during latency in both the peripheral and central
nervous system (22,23).
In the present study, we evaluated the potential of these
vectors to deliver RNAi to peripheral neurons using a
number of approaches. We show that HSV-mediated
expression of shRNA to non-neuronal cells in culture,
primary neurons in vitro and DRG neurons in vivo results
in eﬀective and speciﬁc silencing of targeted genes includ-
ing the endogenous trpv1 gene, which is involved in noci-
ceptive processing and is therefore a potential target for
therapeutic pain relief (25,26).
MATERIALS AND METHODS
Generationof expression cassettes and HSV vectors
The pR19 promoter cassette has been described previously
(23). The pR19-Gateway vector consists of the HSV-1
ﬂanking regions (nt 118, 441–120, 219 and nt 120, 413–
122, 027) that allow recombination into the LAT region
of the HSV genome and the Gateway cassette (Invitrogen)
that allows cloning using the recombination properties of
bacteriophage lambda. The pR19CMVenh-Gateway
vector contains, in addition to the HSV-1 ﬂanking regions,
the CMVenhancer element of the CMV IE gene promoter,
which was ampliﬁed from pR19LacZ (22) using the
(forward) 50-GTTGACATTGATTATTGACTAG-30 and
(reverse) 50-GGCGAGCTCTGCCAAAACAAACTCCC
ATTG-30 primers and cloned upstream of the Gateway
cassette. The pR19CMV-Gateway-WCm vector consists
of the HSV-1 ﬂanking regions, the Pol II CMV IE gene
promoter and a mutated form of the WPRE regulatory
element (27) downstream of the Gateway cassette.
The shRNA sequences against the lacZ and gfp genes
were designed using online algorithms (Invitrogen). A
negative control shRNA sequence that is not predicted
to target any known vertebrate gene was supplied by
Invitrogen. The shLacZ sense 50-CACCGCTACACA
AATCAGCGATTTCGAAAAATCGCTGATTTGTGT
AG-30 and antisense oligonucleotides and the shGFP
sense 50-CACCGCCACAACGTCTATATCATGGCGA
ACCATGATATAGACGTTGTGGC-30 and antisense
oligonucleotides were annealed and cloned into pENTR-
U6shRNA (Invitrogen) downstream of the U6 promoter
between the BamHI-HindIII sites. The U6shLacZ cassette
was then inserted into pR19-Gateway and pR19CMVenh-
Gateway to generate pR19U6shLacZ and pR19CM
VenhU6shLacZ, respectively. The U6shGFP and U6-neg
cassettes were inserted into pR19-Gateway to generate
pR19U6shGFP and pR19U6-neg. The shRNA sequence
against trpv1 (sense 50-GCGCATCTTCTACTTCAAC
TTCAAGAGAGTTGAAGTAGAAGATGCGC-30) was
inserted into pENTR-U6shRNA (between the BamHI-
HindIII sites). The U6shTRPV1 cassette was then inserted
into pR19-Gateway to generate the pR19U6shTrpv1
vector.
The pre-miRNA sequence against lacZ (sense 50-TGC
TGAAATCGCTGATTTGTGTAGTCGTTTTGGCCA
CTGACTGACGACTACACATCAGCGATTT-30)a n d
the negative control pre-miRNA sequence (sense 50-TGC
TGAAATGTACTGCGCGTGGAGACGTTTTGGCCA
CTGACTGACGTCTCCACGCAGTACATTT-30) were
both supplied by Invitrogen cloned into pcDNA
TM6.2-
GW/EmGFP-miR vectors. The pre-miRNA sequence
against trpV1 (sense 50-TGCTGTGTAGTAGCTGTCT
GTGTAGCGTTTTGGCCACTGACTGACGCTACAC
ACAGCTACTACA) was cloned into pcDNA
TM6.2-GW/
EmGFP-miR. The miRNA cassettes were transferred into
pDONR
TM221 (Invitrogen) and then into pR19CMV-
Gateway-WCm to generate pR19 shuttle vectors.
Replication-defective HSV-1 vectors were generated by
calcium phosphate co-transfection (28) of 27/12/M:4 com-
plementing cells with the shuttle plasmids described above
and the HSV 1764 4-/27+/RL1+ backbone described
previously (23). Genome structures were conﬁrmed by
PCR followed by sequencing. Titres were obtained by ten-
fold serial dilution of the virus in DMEM and addition to
complementing cells, which were incubated at 378C for
30min, overlaid with growth media containing 1.6% car-
boxymethyl cellulose (2:1 ratio) and incubated at 378C for
a further 48h. Viral titres were calculated by counting
plaque forming units (pfu) and were typically in the
range of 3 10
8 to 2 10
9pfu/ml. The HSV preparations
used in both in vitro and in vivo experiments were gener-
ated by growing the virus in Corning 850cm
2 roller bot-
tles. The cell suspension was freeze-thawed to release the
virus and centrifuged at 3500rpm at 48C for 15min. The
supernatant was ﬁltered through a 5 and 0.45 mm ﬁlter.
The virus was pelleted by centrifugation at 12000rpm at
48C for 2h and resuspended in DMEM.
Cell culture, transfection and transduction
The 27/12/M:4 complementing cell line has been described
previously (24). BHK-LacZ cells are BHK cells stably
transfected with the pR19LacZ construct. All cells were
maintained under standard conditions in Dulbecco
Modiﬁed Eagle Medium (DMEM) supplemented with
200mM L-glutamine, 10% fetal calf serum, 10% tryptose
phosphate broth, 100 units/ml penicillin and 100 mg/ml
streptomycin. Continual selection was achieved by main-
taining cells in 100 mg/ml of Zeocin and 50 mg/ml of G418
(cell line 27/12/M:4) or 50 mg/ml of G418 (cell line BHK-
LacZ). HMBA (3mM) was included in the growth media
to complement the in814 mutation present in the viral
backbone (29).
293T cells were transfected using Lipofectamine
TM
2000 (Invitrogen) according to manufacturer’s instruc-
tions in 24-well plates with cells at 80–90% conﬂuency.
In co-transfection experiments 100ng of b-galactosidase-
and 1mg of shRNA-expressing plasmids were used and
where indicated also 100ng of a GFP-expressing plasmid.
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in DMEM and the cells were transduced at various con-
centrations for 30min, followed by addition of serum-
containing media.
Rat primary dorsal root ganglion (DRG) neurons
(Cambrex) were thawed, plated at 5 10
3 cells/well on
poly-D-lysine coated 24-well plates and grown in neuro-
basal medium supplemented with B27. Neurons were
allowed to mature for 9 days prior to being transduced.
b-Galactosidase activity assay andstaining
For determining b-galactosidase protein levels, the High
Sensitivity b-Galactosidase Assay kit (Stratagene) was
used according to the manufacturer’s instructions. Cells
were lysed and cell lysates were incubated with a reaction
buﬀer and chlorophenol red-b-D-galactopyranoside
(CPRG) substrate. The activity of b-galactosidase was
quantiﬁed using a microplate reader. For b-galactosidase
staining, cells were ﬁxed with 4% paraformaldehyde
and incubated overnight with 1  phosphate-buﬀered
saline (PBS) containing 5mM K3Fe(CN)6,5 m M
K4Fe(CN)6O 6H2O, 1mM MgCl2, and 150mgo f
4-chloro-5-bromo-3-indolyl-b-galactosidase (X-Gal) per
milliliter.
Animals andsurgery
Experiments were performed using BALB/c mice and
Rosa26 transgenic mice (Gt(ROSA)26Sor), which are het-
erozygous for the ROSA26 retroviral insertion (30) and
express b-galactosidase in most tissues of the adult mouse
(obtained from the Jackson Laboratory). Mice were
injected once directly into the sciatic nerve. Brieﬂy, ani-
mals were anaesthetized with halothane or isoﬂurane, the
sciatic nerve was exposed, ﬁne forceps were used to sepa-
rate the two main branches of the sciatic nerve, the larger
branch being the tibial nerve which was injected with
5–7ml of virus using a 10ml Hamilton syringe. All
animal procedures were carried out in accordance to UK
Home Oﬃce Regulations.
Histological analysis
DRG were removed, ﬁxed with 4% paraformaldehyde
and stained with x-gal overnight. In order to assess expres-
sion of both GFP and b-galactosidase, GFP ﬂuorescence
was examined prior to x-gal staining, as this otherwise
masks ﬂuorescence from GFP. Cell counts were per-
formed in a blinded fashion in whole mount DRG pre-
parations at a magniﬁcation of 40 . For sectioning, DRG
were isolated, embedded in Tissue Freezing Medium
(Triangle Biomedical Sciences, Durham, NC) and imme-
diately frozen in isopentane at  508C. Total 10mm cryo-
sections were cut on a Microm HM 500M Cryostat and
placed on Superfrost Plus Gold glass slides (Menzel,
Braunschweig, Germany). Slides were subsequently ﬁxed
in 70% ethanol. X-gal staining was performed for 2h. For
immunoﬂuorescence, sections were ﬁxed in 4% parafor-
maldehyde for 15min, blocked in Image-iT FX Signal
Enhancer (Molecular Probes) for 30min at room tempera-
ture, incubated with a mixture of GFP chicken polyclonal
(Abcam ab13970, 1/1000) and VR1 rabbit polyclonal
(Abcam ab31895, 1/1000) antibodies in 1% BSA for 1h
at room temperature and treated with a mixture of anti-
chicken FITC-conjugated (Abcam ab46969, 1/250) and
anti-rabbit AlexaFluor 488 (Molecular Probes, 1/200)
antibodies for 1h at room temperature. All photographs
were taken using an Axiovert 200M microscope equipped
with an Axiocam HRc colour camera (Carl Zeiss, Jena,
Germany).
Westernblot analysis
DRG were isolated, snap-frozen in liquid nitrogen and
immediately homogenized in ice-cold RIPA lysis buﬀer
(Sigma) containing a cocktail of protease inhibitors
(Roche, Switzerland). Denatured total cell lysates were
run in SDS-PAGE, transferred to nitrocellulose mem-
branes and blocked overnight at 48C in 5% milk. The
blocked membranes were incubated overnight at 48C
with the VR1 polyclonal antibody (Santa Cruz, 1/200),
TRPA1 polyclonal antibody (Abcam ab31486, 1/1000),
STAT1 polyclonal antibody (Abcam ab31369, 1/1000),
or a-tubulin polyclonal antibody (Abcam ab4074, 1/500)
followed by 1h incubation at room temperature with an
HRP-conjugated secondary antibody (Abcam ab6721, 1/
3000). Immunodetection was performed using the ECL+
reagents (Amersham Biosciences, UK). The blots were
scanned and the pixel count and intensity of each band
was quantiﬁed using the Scion Image software (Scion,
Frederick, MD). Signals were normalized against a-tubu-
lin (loading control) and the result was expressed as a
percentage of the negative control signal.
Quantitative RT–PCR
Total RNA from cultured HEK293T cells was extracted
and DNAseI treated using the RNeasy Mini kit (Qiagen)
as per manufacturer’s instructions. Three micrograms of
total RNA served as template for cDNA synthesis using
Oligo dT primers and Superscript III RT in a volume of
20ml during 1h at 508C. This was followed by inactivation
of the enzyme at 708C for 15min according to the manu-
facturer’s instructions (Invitrogen, Carlsbad, CA). Quanti-
tative PCR was performed on an ABI Prism 7900-HT
Sequence Detection System (Applied Biosystems) using a
qPCR core kit w/o dUTP (Eurogentec). The thermal
cycling conditions were 10min at 958C, followed by 45
cycles of 15s at 958C and 1min at 608C. Validated pre-
designed Taqman Gene Expression Assays (Applied Bio-
systems) corresponding to the housekeeping genes ATP5b
(Hs00969569_m1), B2m (Hs99999907_m1), GAPDH
(Hs99999905_m1), GUSb (Hs99999908_m1) and an inter-
feron response gene ISGF3G (Hs_00196051_m1) were
used to generate standard curves on serial dilutions of
cDNA. The relative standard curve method was used to
calculate the expression values. Values were normalized
against the values obtained for the B2m gene.
RNA from whole DRG was extracted using the Rneasy
96 kit (Qiagen) as per manufacturer’s instructions. RNA
was eluted in 100mlH 2O and vacuum dried to approxi-
mately 10ml. The RNA was subsequently ampliﬁed using
a modiﬁed version of the two-cycle ampliﬁcation kit from
Aﬀymetrix. The reaction was stopped after the ﬁrst
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formed. The RNA was cleaned in a 96-well plate, eluted
twice in 50mlH 2O and vacuum dried to approximately
20ml. First strand cDNA synthesis was performed on 1
mg of ampliﬁed RNA using random hexamer primers
and Superscript II RT. Quantitative PCR was performed
using the TaqMan PCR kit (Applied Biosystems). Serial
dilutions of cDNA were used to generate standard curves
of threshold cycles versus the logarithms of concentration
for Sart1 (endogenous control, mouse squamous cell
carcinoma antigen recognized by T cells) and Trpv1 or
GFP. For Sart1 mRNA levels, the TaqMan Gene
Expression Assay (Applied Biosystems) was used. The
Trpv1 primers and probe were designed manually:
forward primer 50-AGAATTCAGTGCTGGAGGT
GATC-30, reverse primer 50-GGCTCCACGAGAAGC
ATGTC-30, and probe sequence carboxyﬂuorescein-
50-GAGCCAAGGGACCCACCCCATGGAGAGC-30-
tetramethylrhodamine (Eurogentec). The GFP primers
and probe were also designed manually: forward primer
50-AGCAAAGACCCC AACGAGAA-30, reverse primer
50-GGCGGCGGTCACGAA-30, and probe sequence
carboxyﬂuorescein-50-CGCGATCACATGGTCCTGCT
GG-30-tetramethylrhodamine.
Flow cytometry(FACS)
GFP expression in transfected 293T cells was determined
by FACS (ﬂuorescence activated cell sorting) analysis
using the FACS Calibur ﬂow cytometer (Becton
Dickinson). GFP was identiﬁed using a 530 band pass
ﬁlter. The data was analyzed using CELLQUEST soft-
ware (Becton Dickinson). A primary gate based on physi-
cal parameters (forward and side light scatter, FSC and
SSC, respectively) was set to exclude dead cells or debris.
RESULTS
Optimization of shRNAexpression
To optimize expression of shRNA from HSV, we gener-
ated three expression systems (Figure 1). The
pR19U6shRNA system utilizes the U6 Pol III promoter
that has been successfully used to silence genes both in vitro
and in vivo (Figure 1a). Previous studies have demon-
strated that the enhancer element of the Cytomegalovirus
IE gene (CMV) Pol II promoter can improve the activity of
the U6 or H1 Pol III promoters (31,32). Thus, to test
whether shRNA expression could be improved in this
manner, we generated pR19CMVenhU6shRNA, where
expression of shRNA was placed under the control of a
hybrid CMV enhancer-U6 promoter (Figure 1b). Finally,
although Pol III promoters have so far been most com-
monly used for expression of shRNA, there has been an
interest in developing systems using Pol II promoters. Our
microRNA-like expression system (pR19CMVGFP-miR)
takes advantage of the ﬂexibility and variety of Pol II pro-
moters, which unlike pol III promoters, can be inducible
and tissue-speciﬁc (Figure 1c). When inserted into Pol II
mRNA transcripts of irrelevant sequence, pre-miRNA
sequences are readily excised to silence expression of
target mRNAs with perfect complementarity to the
miRNA sequence (33). The sequence of the mature
miRNA does not seem to be important for processing
and can be altered to target the chosen gene (34). To
ensure that the pre-miRNA is properly processed by
Drosha, our miRNA cassette contains, in addition to the
pre-miRNA sequence, 50 and 30 ﬂanking regions derived
from the endogenous miRNA-155. A reporter gene encod-
ing green ﬂuorescent protein (GFP) is co-expressed from
this system and allows labelling of transduced cells to aid
the monitoring of silencing eﬃciency.
To compare silencing from these promoter systems,
we generated plasmid vectors with a well-characterized
hairpin sequence designed to target lacZ, the reporter
gene encoding b-galactosidase. Control plasmids were
constructed to mediate expression of shRNA against
green ﬂuorescent protein (pR19U6shGFP) or a non-
target shRNA sequence (pR19U6-neg) under the control
of the U6 promoter and a non-target pre-miRNA
sequence under the control of the CMV promoter
(pR19CMVGFP-miR-neg).
293T cells were co-transfected with a plasmid expres-
sing b-galactosidase and either the pR19U6-neg,
pR19U6shLacZ or pR19CMVenhU6shLacZ plasmids.
In each experiment, a plasmid expressing GFP was
co-transfected to normalize transfection eﬃciency.
Similarly, 293T cells were co-transfected with a
b-galactosidase-expressing plasmid and either the
pR19CMVGFP-miR-neg or pR19CMVGFP-miR-LacZ
plasmids. Transfection eﬃciency was monitored by the
presence of the GFP signal expressed from these con-
structs. The level of sensitivity achieved with this system
is greater than that achieved with endogenous target gene
knockdown because the constructs expressing lacZ and
Figure 1. HSV RNAi expression systems. Schematic representation of
the replication-defective HSV-1 genome and the diﬀerent expression
systems used to express shRNA. (a) In pR19U6shRNA, expression of
shRNA is driven by the pol III U6 promoter. (b)I n
pR19CMVenhU6shRNA, expression of shRNA is driven by a hybrid
CMVenhancer-U6 promoter. (c) In pR19CMVGFP-miR, the pol II
CMV promoter drives expression of both the pre-miRNA sequence
and GFP. The shRNA expression cassettes are inserted into the LAT
region of the disabled HSV-1 genome. Deletion of ICP4 results in
replication-defective vectors. These vectors also contain an inactivating
mutation in VP16. Prolonged expression during latency has been
achieved by inserting a heterologous promoter after the LAT P2 region.
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RNAi to all cells is not required in order to achieve an
RNAi response. X-gal staining at 72h post-transfection
demonstrated that each of the RNAi expression systems
targeting lacZ substantially reduced b-galactosidase levels
(Figure 2a). Analysis of b-galactosidase expression by
enzyme activity assay revealed that the pR19U6shLacZ
construct silences lacZ by 89.0 1.5% (n=3,
mean SD), the pR19CMVenhU6shLacZ construct by
89.4 4.6% and the pR19CMVGFP-miR-LacZ construct
by 93.0 1.7% (Figure 2b). Transfection with the negative
controls had no eﬀect on b-galactosidase levels indicating
that silencing is speciﬁc. GFP expression levels were
assessed by ﬂuorescent microscopy (Figure 2a) followed
by ﬂow cytometry (Figure 2c).
To investigate RNAi speciﬁcity further, we assessed the
mRNA levels of four endogenous genes in 293T cells trans-
fected with each of the above constructs. Quantitative
RT-PCR for ATP5b, GAPDH and GUSb revealed that
there is no signiﬁcant reduction in the expression levels
of any of these housekeeping genes 72h following intro-
duction of shRNA or pre-miRNA (Figure 2d) and thus,
silencing of lacZ cannot be attributed to oﬀ-target eﬀects.
Moreover, quantitative RT-PCR for ISGF3G, the inter-
feron-stimulated transcription factor 3 gamma, conﬁrms
that silencing is not caused by a non-speciﬁc eﬀect asso-
ciated with induction of the interferon (INF) response.
HSV-mediated silencing innon-neuronal cells in culture
Unlike 293T cells, transfection of post-mitotic primary
neurons is ineﬃcient and often toxic. The shRNA cassettes
were inserted into the LAT region of the replication-
defective HSV-1 genome to generate viral vectors
(Figure 1).
To assess the eﬃciency of HSV-mediated silencing
in vitro, we generated a BHK cell line stably transfected
with a construct expressing b-galactosidase (BHK-LacZ).
BHK-LacZ cells were transduced with each vector target-
ing lacZ or the negative control vectors (multiplicity of
infection [MOI]=10.0) (Figure 3a). The expression of
functional shRNA from the HSV-U6shGFP negative con-
trol (MOI=5.0) was conﬁrmed by the reduction of
GFP levels in BHK cells co-transduced with a HSV
vector expressing GFP (MOI=1.0) (Figure 3b). Expres-
sion of miRNA from the HSV-miR-neg control was con-
ﬁrmed by the presence of the GFP signal (Figure 3a).
Silencing was assessed by x-gal staining at 72h post-
transduction (Figure 3a). Transduction with the HSV-
U6shGFP or HSV-GFP-miR-neg control vectors had no
eﬀect on b-galactosidase expression levels. Transduction
of BHK-LacZ cells with HSV-U6shLacZ, HSV-CMVen-
hU6shLacZ or HSV-GFP-miR-LacZ, however, resulted
in a signiﬁcant reduction in b-galactosidase levels.
B-galactosidase activity assay performed at various times
post-transduction with HSV-U6shLacZ, HSV-CMVen-
hU6shLacZ or HSV-GFP-miR-LacZ revealed that these
reduced protein levels by up to 86.0 7.0% (n=6,
mean SD), 91.0 7.0% and 84.0 8.0%, respectively,
as compared to controls (Figure 3c). HSV-GFP-miR-
LacZ is most eﬀective at 48h, HSV-CMVenhU6shLacZ
at 72h and HSV-U6shLacZ at 4 days post-transduction,
reﬂecting the diﬀerent kinetics of expression from the pro-
moters used. b-Galactosidase activity assay performed at
72h post-transduction (MOI=1.0, 5.0 and 10.0) revealed
that silencing is dose-dependent. Finally, GFP expression
in BHK-LacZ cells transduced with HSV-miR vectors was
not aﬀected by expression of miR-LacZ as evaluated by
ﬂuorescent microscopy (Figure 3a). We can therefore con-
clude that silencing is not caused by a non-speciﬁc eﬀect
mediated by the HSV vector backbone. Unlike oﬀ-target
eﬀects or induction of the INF response, this would most
likely be a non-sequence speciﬁc eﬀect resulting in silenc-
ing of both lacZ and gfp.
HSV-mediated silencing in primary neurons
We next sought to determine whether HSV-mediated
delivery of shRNA could induce silencing in primary neu-
ronal cells. Rat DRG neuronal cultures were co-trans-
duced with a GFP-expressing vector (MOI=1.0), and
either HSV-U6shLacZ or HSV-U6shGFP (MOI=5.0).
High transduction eﬃciencies were achieved with almost
the entire population of neurons being positive for GFP.
Fluorescent microscopy at 48h post-transduction revealed
that transduction with HSV-U6shLacZ had no eﬀect on
GFP expression levels, whereas transduction with HSV-
U6shGFP resulted in almost complete inhibition of GFP
expression (Figure 4). This data indicate highly eﬀective
silencing in neurons in vitro induced by HSV-mediated
RNAi.
HSV-mediated silencing in vivo
To evaluate the eﬃciency of HSV-mediated silencing in
DRG neurons in vivo, BALB/c mice were injected directly
into the sciatic nerve. A single injection (up to 7ml) was
performed to co-deliver a b-galactosidase-expressing
vector and each of the vectors targeting lacZ or each
of the negative controls. In animals injected with HSV-
U6-neg, HSV-U6shLacZ or HSV-CMVenhU6shLacZ
(Figure 5a), a GFP-expressing vector was also co-injected
to evaluate transduction eﬃciency and monitor silencing
speciﬁcity. At day 7, the lumbar DRG (L4/L5) were iso-
lated. Figure 5a and b show representative DRG from
injected animals. High transduction eﬃciencies were
achieved in all experiments mainly to the L4 DRG with
the majority of neurons being positive for GFP as assessed
by ﬂuorescent microscopy (Figure 5a and b). X-gal
staining of whole mount DRG preparations revealed a
dramatic reduction in b-galactosidase levels in animals
injected with HSV-U6shLacZ (Figure 5a-ii), HSV-
CMVenhU6shLacZ (Figure 5a-iii) or HSV-GFP-miR-
LacZ (Figure 5b-ii) compared to control groups injected
with either HSV-U6-neg (Figure 5a-i) or HSV-GFP-
miR-neg (Figure 5b-i). In co-injection experiments,
eﬀective silencing requires co-transduction with both the
b-galactosidase- and RNAi-expressing vectors. In animals
injected with the GFP-expressing vector (Figure 5a),
expression of GFP from this vector does not allow identi-
ﬁcation of neurons transduced with the shRNA-express-
ing vectors. Although a very high degree of LacZ and
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Figure 2. Silencing evaluation from diﬀerent promoter systems. (a) 293T cells were co-transfected with a plasmid expressing b-galactosidase and
either pR19U6-neg, pR19U6shLacZ or pR19CMVenhU6shLacZ. A plasmid expressing GFP was also co-transfected to monitor transfection
eﬃciency. Similarly, 293T cells were co-transfected with a b-galactosidase-expressing plasmid and either pR19CMVGFP-miR-neg or
pR19CMVGFP-miR-LacZ. X-gal staining at 72h post-transfection revealed that each of the RNAi expression systems substantially reduced b-
galactosidase levels compared to the control group (magniﬁcation 10 ). (b) Enzyme activity assay revealed that pR19U6shLacZ silences lacZ by
89.0 1.5%, pR19CMVenhU6shLacZ by 89.4 4.6% and pR19CMVGFP-miR-LacZ by 93.0 1.7% (n=3, mean SD). (c) GFP expression levels
in 293T cells were assessed by ﬂow cytometry at 72h post-transfection. Transfection with each of the plasmids targeting lacZ had no eﬀect on the
levels of GFP. (d) Quantitative RT-PCR at 72h post-transfection for ATP5b, GAPDH and GUSb revealed that the expression levels of house-
keeping gene expression remained essentially unaﬀected by introduction of shRNA or pre-miRNA into 293T cells. Quantitative RT-PCR for
ISGF3G, the interferon-stimulated transcription factor 3 gamma, conﬁrms that silencing is not caused by a non-speciﬁc eﬀect associated with
induction of the INF response. Values were normalized against the B2m gene.
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Figure 3. HSV-mediated silencing in non-neuronal cells in culture. (a) BHK-LacZ cells were transduced with each vector targeting lacZ or the
negative control vectors (MOI=10.0). Silencing was assessed by x-gal staining at 72h post-transduction (magniﬁcation 10 ). Transduction with the
HSV-U6shGFP or HSV-miR-neg control vectors had no eﬀect on b-galactosidase levels, whereas transduction with HSV-U6shLacZ, HSV-
CMVenhU6shLacZ or HSV-GFP-miR-LacZ resulted in a signiﬁcant reduction in b-galactosidase levels. (b) The expression of functional shRNA
from HSV-U6shGFP (MOI=5.0) was conﬁrmed by the reduction of GFP levels in BHK cells co-transduced with a HSV vector expressing
GFP (MOI=1.0) (magniﬁcation 10). (c) Enzyme activity assay 72hrs post-transduction reveals a dose-dependent reduction of b-galactosidase.
Enzyme activity assay at various times post-transduction with HSV-U6shLacZ, HSV-CMVenhU6shLacZ or HSV-GFP-miR-LacZ revealed that
the vectors reduce protein levels by up to 86.0 7.0%, 91.0 7.0% and 84.0 8.0%, respectively, as compared to the negative control groups
(n=6, mean SD).
Figure 4. HSV-mediated silencing in primary neurons. Rat DRG neuronal cultures were transduced with a GFP-expressing vector (MOI=1.0) and
either HSV-U6shGFP or HSV-U6shLacZ (MOI=5.0). Fluorescent microscopy at 48hrs post-transduction revealed that transduction with HSV-
U6shLacZ had no eﬀect on GFP expression levels, whereas transduction with HSV-U6shGFP resulted in a dramatic reduction in the levels of GFP
compared to control groups (magniﬁcation 10 ).
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co-injected (Figure 5a-i), the high levels of b-galactosidase
displayed in some neurons when the HSV-U6shLacZ or
HSV-CMVenhU6shLacZ were co-injected may be due to
incomplete transduction overlap (Figure 5a-ii and iii). In
the DRG of animals injected with HSV-GFP-miR-LacZ
(Figure 5b-ii), GFP expression allows identiﬁcation of
transduced neurons and >90% of GFP-positive neurons
display markedly reduced or abolished b-galactosidase
expression.
We next monitored the level of silencing by directly
counting the number of GFP-positive versus LacZ-
positive neurons in the whole mount DRG preparations.
We found that HSV-U6shLacZ reduces b-galactosidase
levels by up to 78.0 6.8% (P=0.001) (n=3,
mean SD), HSV-CMVenhU6shLacZ by up to
62.1 20.9% (P=0.02) and HSV-GFP-miR-LacZ by
up to 92.0 3.0% (P=0.0002) (Figure 5c). Whereas the
number of GFP-positive neurons remained essentially
stable at 170 53 cells (n=15, mean SD) in each of
the diﬀerent conditions, the level of LacZ-positive neurons
dropped from 464 68 cells (n=6, mean SD) in DRG
injected with the negative controls to 122 68, 148 60
and 63 15 cells (n=3, mean SD) in DRG injected
with HSV-U6shLacZ, HSV-CMVenhU6shLacZ or HSV-
GFP-miR-LacZ respectively. These data conﬁrm robust
silencing in peripheral neurons in vivo induced by HSV-
mediated RNAi. Injection with the negative controls had
no eﬀect on b-galactosidase levels and injection with the
vectors targeting lacZ does not seem to have an eﬀect on
the levels of GFP indicating silencing speciﬁcity. The
number of GFP-positive neurons was found to be much
lower than the number of LacZ-positive neurons in DRG
injected with the negative controls. This is mainly due to
the fact that x-gal staining used to visualize LacZ-positive
cells is more sensitive than ﬂuorescence microscopy
used to visualize GFP-positive cells. Moreover, in the
HSV-miRNA vectors, GFP is co-cistronically expressed
Figure 5. HSV-mediated silencing in DRG neurons in vivo.( a) BALB/c mice were injected once directly into the sciatic nerve with 1 10
6 plaque
forming units (pfu) of a HSV b-galactosidase-expressing vector and 5 10
6 pfu of: (i) the HSV-U6-neg control, (ii) HSV-U6shLacZ, or (iii) HSV-
CMVenhU6shLacZ. A GFP-expressing vector was also co-injected (1   10
6 pfu) to monitor transduction eﬃciency and non-speciﬁc silencing.
(b)1  10
6 pfu of a b-galactosidase-expressing vector were injected into the sciatic nerve of BALB/c mice with 5 10
6pfu of: (i) the HSV-GFP-
miR-neg control or (ii) HSV-GFP-miR-LacZ. GFP expression from this system allows labelling of transduced cells and monitoring of non-speciﬁc
silencing. Silencing was assessed by x-gal staining in whole mount L4 DRG preparations at 7 days post-injection (magniﬁcation 5 ). (c) Silencing
was quantiﬁed by directly counting the number of GFP-positive versus b-galactosidase-positive neurons in whole mount DRG preparations (at a
magniﬁcation 40 ). HSV-U6shLacZ reduces b-galactosidase protein levels by 78.0 6.8% (
 P=0.001), HSV-CMVenhU6shLacZ by 62.1 20.9%
(
  P=0.02) and HSV-GFP-miR-LacZ by 92.0 3.0% (
   P=0.0002) (n=3, mean SD, results analysed for signiﬁcance using t-test) (d) Rosa26
transgenic mice were injected into the sciatic nerve with 5 10
6 pfu of: (i) HSV-GFP-miR-neg or (ii) HSV-GFP-miR-LacZ. At 7 days post-injection,
the L4 DRG were isolated and sectioned. GFP expressed from these vectors allows simultaneous localization of transduced neurons and monitoring
of silencing eﬃcacy. Neurons transduced with HSV-GFP-miR-LacZ are GFP positive and display signiﬁcantly reduced x-gal staining compared to
DRG sections taken from control animals (magniﬁcation 10 ).
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mRNA processing.
The above results demonstrate silencing in a system
where a marker gene has been delivered coincidentally
with silencing. We next sought to determine whether
lacZ could be eﬀectively silenced in a transgenic mouse
model. The HSV-GFP-miR-LacZ vector that was shown
to be the most eﬀective at silencing in the co-injection
experiments was selected for further testing. Moreover,
co-expression of GFP from miRNA vectors allows simul-
taneous localization of transduced neurons and monitor-
ing of silencing eﬃcacy in transduced cells. Rosa26 mice
were injected into the sciatic nerve with the HSV-GFP-
miR-neg or the HSV-GFP-miR-LacZ vectors. At day 7,
the lumbar DRG from injected mice were isolated and
sectioned. Transduction eﬃciency was high throughout
all sections taken from injected animals. Figure 5d
shows representative sections from transduced DRG.
In all four independent experiments, neurons transduced
with HSV-GFP-miR-LacZ (Figure 5d-i), while also
GFP-positive, displayed signiﬁcantly reduced x-gal
staining compared to control animals (Figure 5d-ii).
b-Galactosidase expression in these sections was also
markedly reduced compared to sections taken from the
DRG of the non-injected side of the same animals (data
not shown).
HSV-mediated silencing oftrpv1
We next investigated whether HSV-mediated RNAi could
be used to silence an endogenous neuronally expressed
gene. In preliminary experiments, several shRNA con-
structs expressed under the control of the U6 promoter
were evaluated for their ability to knockdown trpv1 by
at least 80% in HEK cells (data not shown). The most
potent shRNA sequence targeted the region containing
nucleotides 1296–1314 of the trpv1 gene. The U6shTrpv1
cassette was inserted into the LAT region of the replica-
tion-defective HSV-1 genome and the HSV-U6shTrpv1
vector was injected into the sciatic nerve of BALB/c
mice. Mice injected with HSV-U6shLacZ were used as
negative controls. A GFP-expressing vector was also
co-injected to monitor transduction eﬃciency. At day 8,
the left DRG (injected side) and right DRG (non-injected
side) were isolated and analysed for GFP and Trpv1
levels. GFP expression assessed by quantitative RT-PCR
conﬁrmed delivery to all injected animals, predominantly
to the L4 DRG (data not shown). Quantitative RT-PCR
for Trpv1 revealed markedly reduced mRNA levels in the
left DRG from all animals injected with HSV-U6shTrpv1
compared to the control group (Figure 6a). Trpv1 mRNA
in these animals was reduced by 53.6 11.2% (P=0.01)
(n=4, mean SD). Importantly, HSV-U6shLacZ does
not seem to have an eﬀect on the levels of the endogenous
trpV1 gene further indicating the speciﬁcity of our
method.
We have previously shown that the HSV-GFP-miR is
more eﬀective at silencing in vivo than the HSV-U6-
shRNA system. Subsequent experiments were therefore
performed using a vector expressing miRNA against
trpV1. Several pre-miRNA sequences were evaluated
(data not shown) and the most potent was used to gener-
ate the HSV-GFP-miR-TRPV1 vector. To evaluate silenc-
ing at the protein level, 10 BALB/c mice were injected
directly into the sciatic nerve with HSV-GFP-miR-neg
and 10 mice were injected with HSV-GFP-miR-TRPV1.
Eight days post-injection the DRG from injected animals
were isolated. Delivery was assessed by ﬂuorescent micro-
scopy for GFP, which conﬁrmed delivery mainly to the L4
DRG. Western blot analysis for TrpV1, TrpA1 and Stat1
was performed on protein extracted from the L4 DRG
isolated from each group (Figure 6b). Quantiﬁcation
revealed a 59% reduction in the levels of TrpV1 protein
compared to the negative control (average across 10 injec-
tions), whilst the levels of TrpA1 and Stat1 remained
essentially unchanged indicating that silencing is speciﬁc
and not caused by oﬀ-target eﬀects or induction of the
INF response.
The data obtained with both vectors targeting trpV1 is
particularly promising as it represents overall Trpv1 levels
in both transduced and un-transduced sensory neurons,
rather than in transduced neurons only. It should be
noted that the 80% knockdown of b-galactosidase expres-
sion (Figure 5c) was calculated by counting LacZ-positive
versus GFP-positive neurons and therefore reﬂects the
number of neurons out of the population of transduced
neurons. The DRG is comprised of a heterologous popu-
lation of neurons and TrpV1 is mainly expressed in small-
and medium- diameter sensory neurons. Thus, we sought
to determine whether TrpV1-expressing neurons are eﬃ-
ciently transduced by the vector following injection into
the sciatic nerve. BALB/c mice were injected with HSV-
GFP-miR-neg and immunoﬂuorescence was performed on
L4 DRG sections to investigate the degree of co-localiza-
tion between GFP expressed by the vector and TrpV1.
Figure 6c shows representative sections of DRG isolated
4 days post-injection. Our results conﬁrm that the vector
transduces a heterologous population of neurons, includ-
ing approximately 80% of neurons that express TrpV1.
Interestingly, high levels of GFP expression do not coin-
cide with the highest levels of TrpV1 expression. This
explains the 53.6% reduction in TrpV1 mRNA using the
U6 vector expressing shTRPV1 (Figure 6a) and 59%
reduction of TrpV1 protein using the miRNA version
(Figure 6b), as compared to the 80% reduction of LacZ.
DISCUSSION
RNAi has become a powerful tool for modulating gene
expression. Delivery to neurons however poses speciﬁc
challenges. Whereas delivery of siRNAs to primary neu-
ronal cultures has been achieved with relatively high eﬃ-
ciency (35), in vivo delivery of RNAi to neurons, and
DRG neurons in particular, has been problematic. The
development of an eﬃcient method for in vivo delivery
of RNAi to peripheral neurons would allow a better
understanding of gene function, enable the validation of
novel gene targets in drug discovery, and potentially allow
the development of new RNAi-mediated approaches to
achieving analgesia.
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sively used to deliver genes to peripheral neurons, includ-
ing in animal models of neuropathic and inﬂammatory
pain (36–38) and therefore make ideal candidates for the
delivery of RNAi to sensory neurons. However, while a
replication-defective HSV-1 vector has been shown to
express shRNA in the mouse brain to suppress expression
of amyloid precursor protein separately expressed from a
lentivirus vector (20), and HSV amplicon vectors have
been shown to silence genes in tumour cells in vitro and
in vivo (39–41), HSV vectors had not been previously
developed to provide silencing in the peripheral nervous
system, or of an endogenously expressed gene in neurons
in vivo.
Our previously developed replication-defective HSV-1
vectors allow eﬃcient gene delivery to neurons of the
central and peripheral nervous system both in vitro and
in vivo (22,23) and are particularly eﬃcient at targeting
DRG neurons in both mice and rats through retrograde
transport following injection into the sciatic nerve. While
we have previously identiﬁed regulatory elements in the
HSV genome that allow eﬃcient expression of exogenous
genes from heterologous promoters in a relatively non-
promoter speciﬁc fashion (23), expression of shRNA
from these vectors been had not been previously
investigated.
In the present study, we establish that expression of
shRNA from these HSV vectors can be achieved using
(a)
(b)
(c)
Figure 6. HSV-mediated silencing of endogenous trpv1.( A) BALB/c mice were injected once directly into the sciatic nerve with 2.5 10
6 pfu of either
HSV-U6shTRPV1 (n=4) or HSV-U6shLacZ (n=2). A GFP-expressing vector was also co-injected to assess transduction eﬃciency (1 10
6 pfu).
At day 8, both the left (injected) and right (non-injected) L4 DRG were isolated. Quantitative RT-PCR revealed that TRPV1 mRNA levels in the
DRG of animals injected with HSV-U6shTRPV1 were reduced by 53.6 11.2% (mean SD) compared to the right DRG. In DRG injected with the
HSV-U6shLacZ vector, TRPV1 mRNA levels were essentially unchanged compared to the right DRG. Statistical diﬀerences between the two
injected groups were determined by one-way t-test,
 P=0.01. (B) BALB/c mice were injected once directly into the sciatic nerve with 5 10
6 pfu
of either HSV-GFP-miR-TRPV1 (n=10) or HSV-GFP-miR-neg (n=10). At day 8, the L4 DRG isolated from each group were used to extract
protein and western blots were performed for TrpV1, TrpA1 and Stat1. Quantiﬁcation of band density revealed a 59% knockdown of TrpV1 protein
in animals injected with HSV-GFP-miR-TRPV1 compared to the negative control, whereas the levels of TrpA1 and Stat1 were unaﬀected. Values
were normalized against a-tubulin. (C) BALB/c mice were injected into the sciatic nerve with 5 10
6 pfu of HSV-GFP-miR-neg (n=4). Four days
post-injection the L4 DRG were sectioned and immunoﬂuorescence for GFP and TrpV1 was performed to reveal the number of TrpV1-expressing
neurons transduced by the vector.
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ferent RNAi expression systems showed very similar
silencing capabilities. The enhancer element of the CMV
promoter did not seem to signiﬁcantly improve silencing
from the U6 promoter and this system was found to be the
least eﬀective at silencing in vivo. Although the miRNA
system was shown to mediate the highest levels of silencing
in vivo, a more systematic comparison is required in order
to identify whether expressing shRNA from a miRNA-
based system is superior to expressing shRNA from pol
III promoters. However, expression of GFP together with
the shRNA and the potential to use inducible or tissue-
speciﬁc pol II promoters hold clear advantages for the use
of miRNA expression vectors. Furthermore, the miRNA
system allows expression of more that one pre-miRNA in
tandem and it is therefore possible to simultaneously
silence multiple gene targets. Although, as described
above, HSV has been previously shown to express
shRNA, this is the ﬁrst demonstration of HSV-mediated
expression of shRNA from a pol II miRNA-based system.
We demonstrate that these vectors can induce highly
eﬀective silencing of reporter genes in primary neuronal
cells and DRG neurons in vivo. Silencing in sensory neu-
rons in vivo was assessed in an overexpression system and
more importantly in a transgenic mouse model without
any obvious signs of toxicity or inﬂammation. To our
knowledge, this represents the ﬁrst demonstration of
gene silencing in sensory neurons in vivo by vector-
mediated delivery of shRNA.
In addition to the silencing of transgenically expressed
reporter genes, we also demonstrate in vivo silencing of an
endogenous gene. The transient receptor potential vanil-
loid subtype 1 (Trpv1) is an ideal target for testing the
eﬃcacy of HSV-mediated silencing in vivo as it is predo-
minantly expressed in DRG sensory neurons and has been
suggested to play a key role in inﬂammatory pain
(25,26,42,43). Our results demonstrate a signiﬁcant reduc-
tion in Trpv1 mRNA levels in sensory neurons from mice
injected with the vector expressing shTRPV1 and 59%
reduction in TrpV1 protein levels following injection of
the vector expressing miR-TRPV1. TrpV1 has been used
here as a proof of concept that an endogenous gene can be
speciﬁcally silenced in DRG using the vector system devel-
oped. Since the present aim was to evaluate a means of
eﬀective and speciﬁc RNAi delivery to DRG neurons
in vivo rather that to validate the role of trpV1 itself, the
assessment of any behavioural eﬀects is beyond the scope
of this study. Previous studies suggest that only a small
number of TrpV1-expressing neurons have to be reached
by siRNA treatment to evoke an analgesic response and
that knockdown of TrpV1 protein by antisense oligonu-
cleotides, despite being too subtle to detect in the DRG or
spinal cord, was suﬃcient to reduce neuropathic pain
behaviour (44,45). Thus, 59% knockdown of TrpV1 pro-
tein demonstrated by our method would be expected to
confer a biological eﬀect. Finally, we explain why com-
plete silencing of trpV1 is not achieved and that the silenc-
ing eﬃcacy of our approach with respect to inducing a
phenotypic eﬀect will depend upon the eﬃciency at
which the vector transduces the speciﬁc types of neurons
expressing the target gene.
Speciﬁcity has become a major concern in the use of
RNAi. Non-speciﬁc silencing may result from a non-
sequence-speciﬁc eﬀect caused by the virus, sequence-spe-
ciﬁc oﬀ-target eﬀects or induction of the INF response.
Throughout this study, negative control vectors have had
no eﬀect on target gene expression. We also show that the
levels of GFP are not aﬀected by expression of shRNA
targeting lacZ, and vice versa, thus excluding any poten-
tial non-speciﬁc eﬀects induced by the HSV vector back-
bone. Furthermore, we demonstrate that the shRNA and
miRNA sequences targeting lacZ have no eﬀect on the
expression levels of four endogenous genes, including a
gene involved in the INF response, when expressed in
non-neuronal cells in culture. More importantly, we
show that the shRNA and miRNA sequences targeting
trpV1 have no eﬀect on the expression levels of the closely
related trpA1 gene or stat1, which is another gene
involved in the INF response, when expressed in neurons
in vivo.
In conclusion, the present study conﬁrms that replica-
tion-defective HSV-1 vectors can be used to eﬃciently
deliver shRNA to peripheral neurons both in vitro and
in vivo and induce highly eﬀective and speciﬁc silencing
of targeted genes. These results highlight the potential of
this technology, which can theoretically be directed to
target any gene, as a valuable tool for the study of noci-
ceptive processes and the development of new analgesic
drugs. Furthermore, these vectors could ultimately be
applicable to the development of an HSV vector-based
approach to pain control.
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